X4 PHARMACEUTICALS, INC Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax
X4 PHARMACEUTICALS, INC (XFOR) reported Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax of -$65.00 thousand for the 3-month period ending 2019-06-30, per its 10-Q filed 2019-08-07.
Discontinued › Expense Statement › Income Tax
us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax · last filed 2019-08-07
- X4 PHARMACEUTICALS, INC other comprehensive income (loss), foreign currency translation adjustment, tax for the quarter ending 2019-06-30 was -$65.00K.
- X4 PHARMACEUTICALS, INC other comprehensive income (loss), foreign currency translation adjustment, tax for the quarter ending 2019-03-31 was $23.00K.
| Period end | Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax 3 month | Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax 6 month |
|---|---|---|
| 2019-06-30 | -$65.00K 10-Q · filed 2019-08-07 | -$42.00K 10-Q · filed 2019-08-07 |
| 2019-03-31 | $23.00K 10-Q · filed 2019-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |